<SEC-DOCUMENT>0001571049-14-001788.txt : 20140513
<SEC-HEADER>0001571049-14-001788.hdr.sgml : 20140513
<ACCEPTANCE-DATETIME>20140513170706
ACCESSION NUMBER:		0001571049-14-001788
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140513
DATE AS OF CHANGE:		20140513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		14838222

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1400907_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
May 13, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 35%"></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"></TD>
    <TD STYLE="width: 32%"></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"></TD>
    <TD STYLE="width: 31%"></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>0-50626</B></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>91-1707622</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>200
Connell Drive, Suite 1500</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Berkeley Heights, NJ 07922<FONT STYLE="font-size: 10pt"> </FONT></B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices and zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&#8217;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;_____________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>(Former Name or Former Address, if
Changed Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><B>Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#111;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#111;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#111;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&#111;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Item 2.02&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">The information set forth under this
&#8220;Item 2.02. Results of Operations and Financial Condition,&#8221; including the exhibit attached hereto, shall not be deemed
&#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &#8220;<B>Company</B>&#8221;), dated May 13, 2014, announcing certain financial
results for the third quarter ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company will conduct a conference call to
review its financial results on May 13, 2014, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;9.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.&#9;&nbsp;&#9;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&#9;&nbsp;&#9;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><B>Exhibit Number</B></TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><B>Description</B></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 10%; text-align: left; vertical-align: top">99.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 89%; text-align: left">Press release announcing financial results for the first quarter ended March 31, 2014, dated March 31, 2014.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 6pt"></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 8%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 42%">/s/ Paul McBarron</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0">Name:</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Paul McBarron<BR> Executive Vice
    President&#8212;Finance, <BR>
Chief Financial Officer and Chief Operating Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">Date:
May 13, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1400907_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="logo.jpg" ALT="" width="150"></TD>
    <TD STYLE="width: 50%; text-align: right; vertical-align: middle"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Cyclacel
    Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right; text-indent: 20pt">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; color: Gray; background-color: White"><B>&nbsp;P&nbsp;&nbsp;R&nbsp;&nbsp;E&nbsp;&nbsp;S&nbsp;&nbsp;S&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R&nbsp;&nbsp;E&nbsp;&nbsp;L&nbsp;&nbsp;E&nbsp;&nbsp;A&nbsp;&nbsp;S&nbsp;&nbsp;E&nbsp;</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Gray 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CYCLACEL
PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS&#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>--
Conference Call Scheduled May 13, 2014 at 4:30 p.m. EDT --</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.25pt 0 0; background-color: white; color: #666666"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Berkeley
Heights, NJ, May 13, 2014</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;),
a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of
cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March
31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">The
Company&rsquo;s net loss applicable to common shareholders for the first quarter ended March 31, 2014 was $4.9 million, or $0.25
per basic and diluted share, compared to a net loss applicable to common shareholders of $11.6 million, or $1.18 per basic and
diluted share, for the first quarter of 2013. As of March 31, 2014, cash and cash equivalents totaled $28.2 million, excluding
$9.3 million in proceeds, net of certain fees and expenses, from the completion of an underwritten offering in April 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&ldquo;We
are pleased to report that we have enrolled our first European patients in our Phase 3 SEAMLESS trial in AML and expect to open
approximately 80 European sites, trebling the number of study centers,&quot; said Spiro Rombotis, President and Chief Executive
Officer of Cyclacel. &quot;Based on our enrollment forecasts of European sites joining US sites, we expect to complete SEAMLESS
enrollment around the end of 2014 with data readout in the second half of 2015. We are now approaching the fourth periodic safety
review by the study's DSMB. As indicated previously, SEAMLESS is funded to completion. Following Phase 2 data reported at ASH
2013, demonstrating a near doubling of expected median survival of older patients with MDS after treatment failure of hypomethylating
agents, we are designing a randomized, controlled trial of sapacitabine in this underserved patient population, which was the
objective of our April underwritten offering. We plan to disclose our approach to this study in Chicago during ASCO 2014.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Business
Highlights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>Sapacitabine
in SEAMLESS, pivotal, Phase 3 study for first-line treatment in elderly patients with acute myeloid leukemia (AML): </I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Study
                                         enrollment is approximately 60% from mostly US clinical sites</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">First
                                         European patients enrolled as European expansion progresses</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Anticipate
                                         approximately tripling the number of sites that will enroll in SEAMLESS</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>Sapacitabine
exclusivity</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">The
                                         Japanese Patent and Trademark Office issued two patents broadening the exclusivity of
                                         sapacitabine, the Company's lead clinical candidate. These patents claim novel pharmaceutical
                                         formulations of sapacitabine and methods of treating cancer comprising sapacitabine in
                                         combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been
                                         granted in the United States and other countries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">200
                                         Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T:</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
                                         +1 (908) 517 7330 F: +1 (866) 271 3466 </FONT></TD></TR>                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">Dundee
                                         Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382
                                         206 067</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; text-align: center; margin-bottom: 0"><FONT STYLE="font: 7pt Arial, Helvetica, Sans-Serif">&#9;<U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, sans-serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Recent
Events</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">On
                                         April 3, 2014, the Company entered into an underwriting agreement related to the public
                                         offering and sale of 2,857,143 shares of the Company&rsquo;s common stock at a price
                                         to the public of $3.50 per share for proceeds, net of certain fees and expenses, of approximately
                                         $9.3 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>First
Quarter 2014 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>Grant
Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Revenue
for the three months ended March 31, 2014, was $0.4 million compared to $0.2 million for the same period of the previous year.
The revenue is related to a grant award from the UK government, totaling $1.9 million, to progress CYC065, a Cyclin Dependent
Kinase inhibitor, to IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Research
and development expenses increased to $4.3 million for the three months ended March 31, 2014, compared to $1.6 million for the
same period in the previous year. The increase was primarily due to study and site startup costs and drug supply costs associated
with the expansion of the SEAMLESS registration study into Europe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">General
&amp; administrative expenses for the three months ended March 31, 2014 decreased to $1.5 million compared to $2.7 million for
the same period in 2013. The decrease was primarily due to higher legal and professional fees during the three months ended March
31, 2013 primarily related to litigation that was ultimately dismissed in April 2013 with the sale of four Cyclacel-owned patents
to Celgene Corporation for $5.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Cyclacel&rsquo;s
Key Milestones for 2014</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; background-color: yellow"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Sapacitabine
                                         in SEAMLESS:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Completion
                                         of European roll-out of SEAMLESS to approximately 80 new clinical sites</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">DSMB
                                         safety review of approximately 300 patients enrolled in SEAMLESS with 60-day follow-up</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">DSMB
                                         review of SEAMLESS data for futility once 212 events have been observed</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Completion
                                         of SEAMLESS enrollment </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Sapacitabine
                                         in MDS:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Disclosure
                                         of our approach for a randomized controlled trial of sapacitabine in MDS after failure
                                         of front line agents at ASCO 2014</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Sapacitabine
                                         in solid tumors:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Report
                                         updated Phase 1 sapacitabine and seliciclib combination data in patients with solid tumors
                                         including those carrying the gBRCA mutation</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Advance
                                         early pipeline</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.5pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Conference
call and Webcast Information:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Cyclacel
will conduct a conference call on May 13, 2014 at 4:30&nbsp;p.m. Eastern Time to review the first quarter 2014 results. Conference
call and webcast details are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Conference
call information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">US/Canada
call: (877) 493-9121/ international call: (973) 582-2750</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">US/Canada
archive: (800) 585-8367 / international archive: (404) 537-3406</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Code
for live and archived conference call is 41782484</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, sans-serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">For
the live and archived webcast, please visit the Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>.
The webcast will be archived for 90 days and the audio replay for 7 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>About
Cyclacel Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Cyclacel
is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment
of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a
Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly,
and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung,
ovarian and pancreatic cancer and in particular those carrying gBRCA mutations.&nbsp;Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please
visit <U>www.cyclacel.com</U> for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Forward-looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">This
news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results
to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization
of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially
include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the
risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product
candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot;
&quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
&quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
&quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Contacts
for Cyclacel Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Company:
Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Investor
Relations: Russo Partners LLC, Robert Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&copy;
Copyright 2014 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel<SUP>&reg;</SUP> are trademarks
of Cyclacel Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, sans-serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">CYCLACEL
PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">(In
$000s, except share and per share amounts)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">(Unaudited)</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Three Months Ended</B><br> <B>March 31,</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period from<BR> August 13, 1996<BR> (inception) to<BR> March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>2013</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>2014</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>2014</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left; text-indent: -10pt; padding-left: 20pt">Collaboration and research and development revenue&#9;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">3,100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Grant revenue&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">212</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total revenues&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">212</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,297</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Research and development&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10.5pt">General and administrative&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,654</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 19.5pt">Goodwill and intangible impairment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,747</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Restructuring costs&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,634</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,806</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">312,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Operating loss&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,051</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,410</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Costs associated with aborted 2004 IPO&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,550</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payment under guarantee&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,652</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in valuation of financial instruments associated with stock purchase agreements&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(568</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in valuation of Economic Rights&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">547</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in valuation of other liabilities measured at fair value&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,378</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Foreign exchange gains (losses)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,933</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Interest income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,761</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Interest expense&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,567</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other income, net&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total other income (expense), net&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Loss from continuing operations before taxes&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,356</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,446</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(291,710</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax benefit&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">258</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,034</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss from continuing operations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,098</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,877</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(269,676</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Income(loss) from discontinued operations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,705</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax on discontinued operations &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(376</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net income (loss) from discontinued operations&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,081</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,082</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,869</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(281,757</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Dividend on preferred ordinary shares&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,123</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Deemed dividend on convertible exchangeable preferred shares&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,542</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Dividend on convertible exchangeable preferred shares&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(122</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,733</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net loss applicable to common shareholders&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,570</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,919</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(337,155</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net loss per share, continuing operations&nbsp;&nbsp;&ndash; Basic and diluted&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net (loss) income per share, discontinued operations&nbsp;&nbsp;&ndash; Basic and diluted &#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net loss per share &ndash; Basic and diluted&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,790,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,530,332</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, sans-serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">CYCLACEL
PHARMACEUTICALS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">(In
$000s, except share, per share, and liquidation preference amounts)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">(Unaudited)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 6pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">As of</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">December 31,</FONT></P></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">As of</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">March 31,</FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2013</FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2014</FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents&#9;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">31,146</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">28,154</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,718</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Current assets of discontinued operations &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">639</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 20pt">Total current assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,452</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Property, plant and equipment (net)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Long-term assets of discontinued operations &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">48</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total assets&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,785</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,719</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accrued and other current liabilities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,811</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Other liabilities measured at fair value &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Current liabilities of discontinued operations &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total current liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2013 and March 31, 2014; 335,273 shares issued and outstanding at December 31, 2013 and March 31, 2014. Aggregate preference in liquidation of $3,989,749 at December 31, 2013 and March 31, 2014 &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&#9;&#8210;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&#9;&#8210;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2013 and March 31, 2014; 19,369,332 and 19,819,332 shares issued and outstanding at December 31, 2013 and March 31, 2014, respectively &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Additional paid-in capital&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accumulated other comprehensive (income) loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(101</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Deficit accumulated during the development stage&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(289,430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(294,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total stockholders' equity&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28,023</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,975</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total liabilities and stockholders' equity&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,785</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">SOURCE:
Cyclacel Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, sans-serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`<`$L`P$1``(1`0,1`?_$`+P``0`"`@,``P$`````
M```````'"0@*!08+`0,$`@$!```'`0$```````````````$"`P4&!P@$"1``
M``8"`0,"!0$""0@+`0```0(#!`4&!P@`$1()$Q0A(A46"A<Q&%$R(R27>-@Y
M&I$E)G:V6;DZ08%3TY0HB+C(&4I:$0`"`0,#`P,!!04%!P0#```!`@,`$002
M!08A$P<Q(@A!46$R(Q1Q@9%")%)B,Q46\*&Q<H)#@]'A-!?!)2;_V@`,`P$`
M`A$#$0`_`-_CBE.*4XI489:S3BK!%46NV7;U`T2MI*&02>S+D_N9)X5%1S]-
M@HAHFZF;%+&;(G4*T8-W+HR:9C`F)2F$+_QSB_(>6[@-KXYB39>:1<A!T47M
MJD=B$C2Y`UR,JW(%[D5C'+.9\6X-M1WKEN=!@[<#8-(3J=K7T11J&DE>P)T1
M([V!.FP)%&FP7G#3`)"`UGQJ<YP,*".1,H]"I_*HZ0<+0]"AG8G4(JF"2[1T
M^DTS!U$J\?\`M+SJ[AWQ5_!F<YSOO.-B_P#20'R''_,KHD7V%)JXBY]\UR>Y
M@>-]MM]!EYO_`%!C'BQG_E:.22;[1)CU6#8?)1O%9E`5D=A;6U,"8I`6O151
MJ:?8(&#J*56KL.F90`-\#B`G_9\>H!S>V'X0\58*Z8=FQV%[_F--*?XRR.;?
M=>WW5S?E?)'S=FMJFY!D@E;>R+&B%OV10(`?O`!^^HI<;B;:N3@=39W8$I@*
M!`!OF'(+4G0!,/44VM@13,;J;^,(=1#H'7H`<R!?&WCM!8;#L]OOP\<_\8S6
M(MY<\JN;GDV__NW#+'_"45^F.W/VZC%@7;;-YX5.4P&`LCE6ZRZ/4H&``%M+
M3+UN8O0P]0$H@(]!']@=))O&7CF=-#[%M`']W$@0_P`413_OJMC>8_+.)*)H
MN2[X7!_GS<B1?WK)(RGU^H/^X5-M)\I&\-)>-5B9I=VJ/1>IO'4-=JU5;&SD
MRDZ`9DZD5X9*RM62P!T,5F_:G#]I3%'X\Q;<_`GBK=(V4[6L$I4@/#+-&5O_
M`#!0_;+#Z:XW'V@BLVVOY/\`FW:YUE_SDY,(<,T<\&-(K@?RLW:$JJ?0]N1&
M^Q@>M6S:U>;#'=K*A`;-U@<9SIU!*2\TB/EY['[@G8Y5$9.!%Q,7.NJ`8J2*
M0(?64U3G$ZAVQ"\YYYQ\7-YP"<O@F1^NQ;?X$[)'D`]![9+)!(/5CJ[)4"P#
MDUU-XZ^9_']R087DO%.W9Q)_J<5))<4BQ/OBU29,9Z!0$&0&)U$QK5V55MM6
MO4!&VNE6."MU8F$CKQ-AK4JQFX222265;*G92<:NY9N01<HG3/V''L4(8H]#
M%$`Y;W#;MPVG,?;MU@FQL^(V>.5&1U)`(U*P#"X((N.H((Z&NT-JW;:M]P(]
MUV7)@R]LF!*2PR+)&X!*G2Z$J;,"IL>C`@V((KL'/%5PIQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J
ML]_?)5`ZBO8_'-%@(C(68Y2/+*OH^2DE4JW0HMR031CJTHQARR3^6EP`%&\8
MFLS5]H(.5%DR';E<[^\0>#LOR-"^][M-)A\:1]"LJ@RY##\8B+^U43T:4JXU
M@H%8JY3F#SO\D-O\3Y"<<V3'BW#E\D6ME=R(<56'Y9G">]W?HRP!HV,1$C.@
M:/7K+Y>S?G[<')C.4N\K9,BV^8D%(^FTFNQ[YXPB!DCH$1KE"ID41S[8JQ6J
M*8E025>O3I%4<J.%Q,J;NGCG%N(>-]B;'VJ.#"VV)-4TTC*&?3<F7(F>U[78
MW8A$!*H$0!1\V.6<TYUY:Y(F7O<N1N&[S2:,?'B5F5-9`$.+CI?3>RBR*9)&
M`:1I)"6-A>`?"[L%D,&<UF>=@\(5M<AEABC@C<\@KE_FJK8HP<4^;UZ);O4%
M5`$[F5%ZU5(`*,AZB`::YA\G>&[+JQ>,Q2[KG`VU"\../4'\QU,CE2`0$BT.
M#TE%=`<"^'7/^0F/,YC-#LFUGJ4-I\MA[2+1(PBC#`L"9)NY&P]T#>E2I==$
MO%_@8SIIFS<2W/[%$RYH^2K--GJA(SC)TW$#J1,[3*E1\@6R)4'IV**+&:`7
MN_C$'H/+!M?ECSSRT+)Q?C6,F')&&66=)EC93Z/'--/CQ./J`NN_V$5E6^^$
M?C%P=WBY;R[-;-CE*-#CRX\LJ,OXDE@Q\7)FC-Q8EQ&!Z7!ZU%[W)/A3@GKQ
MDAK[L/=$!$Z:,LRFI]JR`$E5T@69IR.;JG(]')`*J`.&PB!!*`E*;O(%^38_
ME!EQ)*V\;)BOZE"B%NH!LQ&#*O3J/:WK?J18UBK\C^&N%-)"NP<BS$]!()'5
M>A(NH.Y0/UZ-[T]+=`=0KJ2+?PVY&DR@9_ME@1L0@D[G*<+-12IB>@4%5"M&
MN9IOJMZYC="]@?R)O@7J0#W)W^2VS8Q(3CF[27^AD1_KT&HX<?2P'6YZCUZV
MM"1?$+D&8+R<MV.'3;W"&2*_3J=*Y\US<GI8=#T!TWDN$\6N!=@8"0GM/-RZ
MQ>Y!LS%VA3+Q!^RF&Y3O#MD5+0,<JQN-2:'!,P$4<5=3US%ZD#M,'2Q97GOE
MW#LM,7R5QC(Q(&:QG@DU(?;>T6H&&5OM"Y0T@]>HZY/B?&7@7/\`!?-\/<PQ
ML[*2/5^FRH],@]Y75+HT9&.E@0I?";61=38]*SMAM6\W:MV5I6LQTY:`&7!^
MM6I]D[:3%7M+*.>':+O(.;CU5FYCE#TU3LW(-Y%L@X1,X;(^LF!MY<-Y[Q;G
MN`V?QG)$RQZ1*A!26)F74%D1@"/J`ZZHW97".VDVYMY_XTYGXRW--KYAAMCO
M,',,@99(9T1M):*1"5/\K&-M,T:O&98TUJ#W'4_<_,FH%G>S&.7K&5K<[Z9;
M50+*#UU5)_TR^FD_]!F[9N8N?9I?!N];J%.'0"*E61[D36SR%XQXSY(P%Q=[
M1X\V*_:R(K"6._4K<@AHV/XD8$?52KV87KQ5YCY?XDW1LSC[I+MDY'ZC%EN8
M9@+@'H0T<J@G1(A!!L'61+H=J#2/>S'6YU5E5(J/5I63*D5`]RQV_?$D%&[%
MVH9)C9*U+@V9%GZX[5+Z*I_11<L70>DX2*FJT7=<!>5/$N]>,<^/ON,K8<@D
M0Y*KINP%VBE2[=N4#J.I61/<C$K(D?T]\*^<^/>8]ME&/&<+DV(`<C$9M?L8
MV6:&2R]V%C[6]JO%)[)%"O#)-G/S4];QIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*J_\B?D)@-4:V\QY17!
M)386S0+:0KS1:+._A*3#RCMTQ3ML^LX].-=/RD8.1CX\!7.9<B:KI'VIB@OO
MKPOX;R_(.<F];NI3AD$Q60AM+SN@#=F,#W!?<O<D]HTZEC;N`E.9?D)Y^P?%
MNV2<>V)Q)Y!R8%:)3&6CQHI&=?U$A([;.-#]J&['7H>6,PD"37#P#JSL;O+>
M+;*4\H3SXLD25R!DJ^S;EM$-I:P.5EA<3,P9"3EI65?'*JN9)JW=./3()A(`
M=O7MCF'/^%>*MJQX-S/9AT:,?&QT!<I&`+(EU1$464%F1+D"]?._@7BWR'YK
MWC+R=F'?F$FO)S,J1EC$DC7)DETR.\CDER$61[78CTO?O7:SIQX?*(PFK9(V
M"Z9:R,S6BW-@91#1[>K:UADV[V295F!7E&\-2J2A*'1,H11[WK+J-RN73LR"
M(H\@YN?Y+^26ZOB[<D.)QS"8,(V<B")GNJM+($+SSE-0!"650Y2./6VOO#;=
MJ\0?$?8US]VEGS>6[@A0RA%;)G6,!F2"$N$QL8/I+7DNSF,2RRE(]%1.Q?DC
MVFW#D%\64**D*12K@8T$SQ1C%M(V.WW)%V0`/$SMA:1Y;'9E'9/5349QS:.9
M.FQ_37:K=!.;HWA7A+@/C6$;_NLB96Z8WYAR\HK'%"5_GCC+=N(#H0\C2.C=
M5D7T')?D+Y$^3_+\[<7V6)\/9LS\I<#"#S39`;UCEE5!-/J%U:.)(HG3H\+=
M2>,J/B.W@M+=!T\QU`4Q!R#4Z(VZ]U=!QZ#HI3^NNP@9"P2+(6Q3?RJ*Z*;D
M@]2^F)@$.5MR^17BO;W,<>;-E.MP>S!*1<?0-(L:M?Z,K%3ZZK5)LOQ-\T[O
M#WY\'&P4(4K^IR8@Q#"_X(3,R%?YED5&!Z:;WKL,]XG,KU-\$5;=D=-*I+"B
M5P:)LF8[##21$C**H=YF;[':*W8"[=1/N`!+WIF`!$0'GEP_D'L.XP_J-MV/
MD^3C7MKBPHW4FP/XER"/0@V];$'ZUZ-P^+?)=HG_`$F[\EX;B9FF_;FW&2-P
M+D7TMB@^H(OZ7!%^E$O$+LW-1Z4M0+GK]E6,6]3MD<>Y15E&("DHHB8/>2M<
MA6IQ]R@HE\IS=%$S`/3IR#_(S@V),<?><7>=OR!;VY.+H;K8_A61SZ$'T]""
M/6JV/\2_(NY0#*V'<..[EB$'WXN:TB="1;48%%[@K]EP02+5A]F#6G9'56>B
M7N3:#;<=NV\@P=UNZ1S@CR!&82.N^C1@KY5GK^$3L#;Z>9P5NF\)(-@("ADR
M?`>;(XUSCA//\22/8<S'S8BC"2%@1)H-E;N02JLG;.K3J*=MKV!-:?Y?XX\A
M^+\Z&3D^!E;?,)%:'(4AHC("73M9,+-'W5T%PBR"5``Q5>E9X:Y^4!;[3D,&
M[OUAWL;AJ>318_7IA"-F[U6VZ358$C/OJ0-%KMZ<D5!=%^N_;SD:IZCA%TX.
M1N@34W-/!"C<4Y7XKG79.3PDMVT+)CRFXN!IN(+KJ#1K&T$HLCQJ&=SO'Q]\
ME7;:GX/YKQFY%PS(LIEE"R94`"FQ.H!LDA]++*TJ9,)U21RNRQQCZLD^..%S
M?&(YF\=5E:YAQA/2C]O*8VFYZ+K5VQ=+%.@L:O.7=XD8,[UBV!<_H$D3HORL
MRH*%5DB+`[/-LOFK)XK.>,^:(&VS?H8U*Y,<;RP92=1W`(%DTL;#5VP8]9<%
M8"O:$.0?'C#YKC?ZP^/F6F\<9FF8/ARR+#E8;W![1.2T6I%N='>*2]L1L&R0
MW>:4=:*&X\15?S'O;O\`SL)@[#]6QN;'Z44WEF=\NEDLMSNU14@HJ#@J"M9$
MI=Z_=014DFR2YE2BM[E;T&C5TNEJ?S_Y=X;S;CF-QWB\LF5*F:D[2F)XXU5(
MI4TCNJCER9?HFD!6N>HON_XP>">?^.N5Y7+.9Q0X4$FW28R0B:.65FDF@DU-
MV3)$(PL)Z=PL69?;T-K$_'OYK/'UY-;'8J%K'E686RE5X5Q9Y7%61*?-42[*
M51L];1R]FADWZ;BO66+;/'B)'`1L@[<LO62,Z20*JD)^2K'ZUW&&4FRF]6O\
M5&G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2NGY!OM5Q=2+3D2\2R$)4J;"/[!/2:_4P-V$>@990B").JSQ\Z,`)-F
MZ0&6<N%"))E,H<I1N>S;1N&_[KC[+M49EW'*E6.-1]68VN3Z*H]68V55!9B`
M":M&_P"^[9QC9,OD.]2"':L*!YI7];(BEC8#JS&VE$6[.Q"J"Q`K3(FC9G\D
M.W4P\K<.96U9+GA49,W"YSP&-\?1!4(^/5G)1JQ23;P50KZ*)73HC8JT@[ZB
MFBJ\=D24^F^*.+^$_'4<6;+IVW!ALS`?F9.0]V;0A8WDFD+%$+Z8UZ%UBC++
M\=,U^;?(GRK++@1%]XW&;V(S$PX>*EE7N2!`%AQX].N01AY7NRQO/,$?8SME
MIP)XF]3V4##`A+69V#O[;A%#E1LN7\I.(UHA*6>6;E<K+1M?:>V;GD'`&,WC
M(\B#5(5'"C1%?BO;\#EWR'\AOF9-XMO2W<<=8\/%#$I$AL`\K781K;5+(7D8
M+&LC)]"]UW3@OQ4\5Q[?AE9MVDU=F,])<_-**'G=0Q,<*Z4,K7TPQ".)6:5X
MEDH,P[@_8_RA9YL]PL5C%!M[ALYO>2IAB\7K5-B#+E+'U:J0Z"B2+IZV9*G&
M.B$W#<AB$,HNX3[CKFZ\Y+ROA/@?B4&VX<%WTD8^*C`2S/;W2RN02%+6[DQ5
MC<@(C6"5PKQ'@WD?Y+\UR=ZSLBT1<'*S95)A@2_MA@C!&ME0_E8ZL@M8R21A
MM9M2ON9](?%I49>DZ^0$%DW95U$J1Z\D[=M[1.MG;E9-!5?*5W8"V2KD4W5B
MRN%*S$>S6<*I(&,V:%<_4"Z!VCC/E3SYN,6Z<RFFP."K+J"*#$C!02!BP-<R
M.0Y494VM5#.%>0H83TYO_+O"WQ@VN;9>`8\&Y^36@TF1R)Y%+D=<S)72(H_8
M)#A8QC:0K&6CB$HR:K/LV2?)MO%(BT91^:YNIV51RS;UZB0$SC_#R49,&^J-
MHN:E6Q8:JR$4DW(4&KFQ2+Q<4@*`N#F,(FWE@;)X,\50]R1]JAW"``F2>1,C
M,+(-#,BDO,KD_C3&C1;DV0`6'.6Z;_\`)3S3.(1'O<^TY=PL6/#)B[?VY29$
M61U$<#Q``".3+ED8J!>5B;GFJYX<-UYMN=:3@<>T]0A&YBM+'?XYTX5,N0QU
M4R&J3>TM`.S,4"J=RI2B8P>F)PZB'ES?DKXMQ7"P3Y>2#?K'CN`+>E^]VCU^
ME@?3K:O7MWQ$\T9J%LG%P<-A:PFRHV)O>]NQWQ[?0W(]1IU"]H>N/CGWJQ'Z
M5E5PA<W/TV11^GR^,Y:&O,PBZ3.!F\@RC*!-3-L9)I'`#`N=HCZ73J82].9)
MMGFGQ1R$G"CW;%76AU+DJ^.A!%BI;(2.)B?0J&:_WUB&\?'OS;Q95W"?8LUM
M$@T/B/%E2!E-U<)B22S(`1<.473TN0:F3#/DTV;P,#_%VP5>=9XH#U%XQLU$
MSBC)EO18N3;RA'D<G:K"RDI)TPD%WQ/7;3K*90,T0]LW*U(83AC7)?!G!>6E
M-^X?,NT;RC!HLC`*]G6I2S&*-D4,H4Z6@>!M;:W+D`5F/%/D;Y.X().,>0,9
M]]V"5"LV)NBN,@QR+)=1/,CN4D+KJ7)CR4,:=N)8PQ:N^9JT]Q#MA55=A/',
MQ3=(L_=?JQKJ]=?1;I4YA4J,H5]5J_*OG30S59!VJ4S)B]5CCG0!&),L8JC5
M&T<8\D<C\?;@.&^:GTN^G])N*C7!,G5-,TB*"&!46>1%DL2^1I!61[YS'Q'Q
M/RCM!\@?'F)FB1G_`%VU.Q3(@DLLFK'B<L&4AS>.*5XKA8\340T29`^,ZONM
M$8',>;]U+C3M1\2W(E(ID!);$WJIX>B[#:VKNPR"7>:^3L$5B]CF2JB;4CHB
M2KL'BOMP."2W;J[Y,\WXER:+;-KX_E09V;C23.\D)#I&KJ@"B0`HQD*W(1FM
MVP7`NM]T_#SQ[S?B#;UN_*<#*V[!S(\9(DR%,4DC1M,68PM:11&'`#2(M^X1
M&6L^G'+\D_%$KY2?%?6KSX][I4-O(S!&RU9R99X'7"WQF:S6R$CZ5?,=SZ%/
M:XM/;TK/>:0]R,R>KQQ#IK-X4T@O\3ID15Y-'0]:[=<%EZ5KM?B[>,?=M+R:
MXAVWO&`LFX=P-KQ7<IS5BO&7J/;<<L;O)Y(Q)DG$%=I^,D[-#QR]YG$Y>V'?
MR)V95&$4PCU/>.$'+F.;O)B1:J:(P;J"*]-WDE5Z<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*U_?.1GA>.A,6:X0K
M]1`]A.ME.]MT3/FZB\+&N'<!16"RJ2R;&0BY";1EG2[=4B@INHMFJ':(%$>P
M_BGQ))LG<.;92`B&V)`3I-G8+).UB"RLJ&%58$7665>MS7`_S:YR\&+M?CK#
M=E,U\[)`UB\:EH<52P(1T:09#O&P:SPPOT(%\F/#CA!MC;5HF2'\.=C;<W3[
MVQ.7KM)RA(*TRO.'<#3&1F[@B1$XXYTW\FU4(4?<(R@*>H=,4@)@OR7Y5)O?
M/O\`(XI0^W;5"L846*B:4+),UQ>[6[<3`GVF(K8-JOLOX@\*Q^/>,!R62%DW
M?>IVE=F#!C!"[Q8ZA38!#:29&`NXFU:F31:K_.I[-Y2?(*?'6-Y)JVQE0F[B
MJ,;>B47T;%XWJ$J8;GDCM:/GC287L]DE#IPPI"V3>HN(M%<4.BRY=]<37`\!
M>'?\ZWR-FWW+(E:$^UGR9D_)QNJ@H(HT!FOK*%<AT#^U#S'S>;=?D]YY_P!.
M\<E5>-80:&.87>./#@<?J<VRNRR&>5[0%>V)5;$BD,=FD&;_`)'\R,]0,%XJ
MTTU?1^U;'>HL8L[*KD.I;(J@@N,6=9M]/!*14MV4[0NNF:1`BKEX=O(#\'"I
M%2:K\)<:F\D<LW#R=SL_J,/$DU`R_P"$V1;78ZKJ(<2(*1&2%0-#_(I4[K^1
M7+\;Q)P;:_#OC4'%W'-BT%81>9,6Y0FZ6?OYLQ8&0*S2:<B]G96KH&M.AN+-
M(,=+[A;HN&\C;J3')6*MXW:J1\C'5&P"*:T$S124>-X^ZY5</"D;QZ0N"Q$>
M[4,KWJG21?-;QSCRWO\`Y3WH>-O%ZLFWY3F.7*(96EC])"2%+08@!+2-I,TB
M@+90S126'QOX+XSX7X^WEWS*R2;KA1=Z#"!C9891[HU&IE3)SF8!(4UB"*0E
MKNRI-#',]NKY#-\)^7J^HM`G<98P]XYB%K'7R-FDBW0]O&G7^[<S3I6</79M
M(AO>(LX(T?))H./2*+X2E5/>\/Q=X:\28<6X>1<N'.WW2'$<MV4F[`=G"34\
MD?\`(SSB6,LNH]JY48WG>9O/_G3<9MI\4X,^V\:UF,RP`*ZC3&3^HW&32D,H
MZR(F,8)0CZ!WRH=NM2'A9VXN;YS/9`SGBJ9L+DX`M)25GR7;9!RD`=Y1=RTS
M3&;PR@*G/\OSE#]H&^(@'MA^4'CG;8EQ-IVO<8L-1T58L6)1^Q$G(MZ?9^RK
M?D?#7RUNT[9V];SM$V<YZN\^9,[?\SOBAB?X_MKI<CIEY2]/TDIG$UJMEDKL
M,9&:<M<&Y!F;+!BZ0!%D@W?XHL#:%D+<J5#M`420$B@"1/FZ%*'2Z0>3O`?D
MEOTW(8,:'-D!0'/QTCD"FY)7+0ND-S>Q_41MJ/3J:LV1X<^3?B)?UG%<C+GV
M^(K*PVS*DFC+`A0'PI!').0+7'Z65-(]W0&TJ8JW"U\W?@V6OOD*J<57\GMO
M]'J)GV+8-JK)(3#HXQIF\E(-V?90;"$BH1P<BJ"E5?+D'WC1MZ"2:]@W_P`;
M<R\69;\O\-9$DVQM^9/MSL95*"S712UYTT@J"&&6B](I)-;%,GXQY=\?^:<&
M/@GG_%B@Y&@$6-NR*L+]QB4M(RH!BN&*N0RM@R-<S0PB-`\WX5UCQUX@U,];
MI;6;&T^$P/1L>A5B6E&"M3=S]+L]NJXE>6"M1C:;DU;`\G8V/CXN%B0G%Y!V
M^#L$%4TB'U5Y>\X[=Y*XMA[%@X$V-DKDB><R,CJK(CHJ0LHU.#W&+2,D1&D*
M$8.2-V>"/CCNWB'FFX<EW3<\?,Q'PVQL<1))&[I))%(\DZ,=,;*8558E?(5M
M1<R*44&I[R[UFE?DP::T.X>(_+%-SKD/3K,4HXR1A"W?4<,WYW%9.JHLHM=C
M^JS:I1D<Y=*U@%HMQ(*-(&8;HR::,H60BEV"G.(Z'K763$.MEZ]?_6LP_P`8
M_P`0>RWB[Q!L=<=KEJW6LI;/S.*>S#E=G(NX.,:5K#B&24HYS:[E7'TA49&U
M6R0R8\,=E$.9%BR8,FJ@OE7#I=JQ$WI&I4=:VA.0JI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5T":RICBO6-U3Y:Z5
M]M;(^"C;7+5@D@B[L$#3Y=W.1\9=;'#,A<2%<H[V0K,BW)-/DV\6+ABNGZ_>
MD<H*5R7W_1/L7]4?O6I?IG]I_?GZB_<</]B_8WTC[@^\_N[WGV_]I_0?Y]]1
M]Q[/V?\`+>IZ?S<4K5)VYK<UM'Y3YW%:BTQ[.;RA1,7$!H<'KFN4^"B(%C:I
M2*0<&.W0;Q[-O)S)T^@)^H=4XAU,;K]&?'&;B\#\!0[^HCUPX&1E'5[1+,[R
M-$C$=268QP@^M@H'H*^3_F#:L[R-\H)^*NTVC(W+#PP4]YAQQ%")9$5N@$:=
MW(8?AOK8@W-[X/('E)'5K2:X?INLWI,F:'K&'\7MXDB[(L$G+"VA1;5]1DJ@
MM%/:[06$@XCU2&`6RS-,Q?B4`YR5X<V!^?\`E+';>U.5`))<W*+V.LK=P9`0
M0ZR9#Q+(I'N5V!]:[A^0'*$\8>%\I..LN#E-'!M^$$!7MA[(5B*D&-HL2.9H
MF!]C1J1>UJP\\250@\`Z:97VBNS4B32SK6^XJOH\B3V54QGA^.DV9VZ2)@04
M)(*6:/G?3;>IVK`"!NH"8`#9/R)W'+YAY,V[@.UM>2`0PZ6NJ#)S&4@GUNHB
M:`EK76[CZ5J3XI;9@\$\.;KY-WF->UD-D9&M`K2'#P$92HO;W&>/)"QD@$Z#
M?W=(T\9E?7SCDG87R&[(A!.2PLBZ2K5DL`D^C5%[#Q/URVR\6F^=J%A8C'=+
M+&,6#E0BOI-E%0(L51!437WSIF+Q79-F\-<'[R]Y!W(H[ZY5=]$*,54:WR9S
M*\B@B[@%ETNM8U\;,(\UY!R+S_Y(&,[02?EY$H`B@>*+N9$B*S'MIB8PQXXW
M8,5C)"R:D<GB<=#-^0[)60=LMG)YQ5]%L!S$Z_J&.9DRS>%E2044HN"<A&P[
MI99X^CHQ1!].O1%VL]>.PBV'>W$Z;3T[T,3PSL>'X[X'",CROO$4:RY*6+KK
M>VI6<`*K-JCQT]BQHAGFLX#2^/C<F?\`(#DN?Y7\ES'&\([!-+)!B2#\MNW'
MJ",D;,79$T2Y4A[AEDD&-CAHV9(98QE9-OMY3LOW=5VND&D%<D96O5.5KD%%
MQ=\N$/&&6:'5K+")313:K(2"1DCA%N8R&C%W#A$'<L\8'#F.[]@^-_%"M_K4
M-RKRI.B23)+([P0NUF`E9[W!6Q'=66>551NWCQ3"LKXKNGESS9(A\>:.%>$\
M>62&%XHHTR9XUNI,*H+!P]P3`T./`[2()LJ?&-\DGGB6UCL:<FXR+9L\97LD
MF"IQNF1,L2$Q9VCI9,R1WS=PQC8J-<.O3!(O5VU<E$&Z8&`0`W=A$7R+YWA=
MN/9L?:-OP8[?DX^($B(!OI(9V8#U_`R'W-8^EMB3?$[QIN!FGW_*WW=-SFO_
M`%&5FF296(L6#+&BLWX?\1)![%N#UO"^1M`]M,(QOU[2/;G+;UO!-DE&&&<J
MVQ"48N?:%<.E4J[(R21,>F<NED&K=NQD85DV],3BO(=GR#D^R^8/'?*Y_P!)
MY4X[MZRRDZLW%B*L+V`[BJ?U(`!=FDCGD:^G1#?W##]_\#^6."XWZWPGRO<W
M@A0!=NS9E=2`"Q[+./TA9F6-$CDQX5"Z]>1;V&0\`ZW4#<S'==S5NMJPA7=A
M8Z7=UZQO)6+O>+GUV;UH(]O!VN?J#27@BR(/8U-%LH5^@NW4.U4!`B;0R;<E
MEYCSC>/&>]3<7\7;^9N&/&)(E1X,M8#+J,D,<S))ITL68=M@P#KK+2`N<DX#
MXYV'R]QS$YIYEXPD'D%)629I(LC"?)[)58II\=9(^YJC5%83(4)1Q&B0,J5A
MM1KY(^;ZT^6CQP[XZ:V["NONN66J-0\46]!_:JQ?K,*<[D(U:R@PLTNU;0JE
MH,-"BK=!GB6<E7E(6=1:OOJ;!9->5YY].M=2CW`@CI6<?B_\0FI'B4I>3*IK
M&.3I^7S%,UR5R/D++]NC+1=+(VIB4\E2H$Z57K5'I49#50;9*F;>RAFSM8\@
MJ+I=QV(`B)O454+Z5:1R%34XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*50/MC@S9BTY&N,/AS/EMU+M#2H;HS=AE(N
MWJXV@-RLI9VO>N<KJHQ9Y#<4^S)3\]4==\.6/&SJPQ_9DW$*D;'GBF:M><0Z
MDS$>EOK4&];CTM61/Z76C[-_5O\`3F\_N[?OT?O9_NY?95M_5?\`1?\`0#[8
M^XOT3]W];_4K]]7_`,Q/T/V_WI]1_P`Z?2OU&_S9R%.M85Z75EK?O,+LO9IE
M=P#[%]EV1LT&5(P`FLZ;WY/$:"#H.GSMTJY<US`'_:ID'_HYVWY/SWVCXV;'
M@XRKVL^#;8GO]`<?]82/O,D"C]A-?.SP[MJ[_P#+KD>YYKMW]KR=WFCMZ$KD
M_H%5ON6'(:WWJM3!YV[JNPQC@'')4^K:U7NVW59;M*/8O0*^P@FR?>(]Y?53
MR4J/0`Z#V?']@<QOXF;7'-OF\;T3^;CXD,`'W9$C2$_N.,O\?VUEGSCWJ6#C
MNP<>`_(RLW(R2>G1L6)(E'V]1F-]W3K]*E/R/)-M:_&=6\*1!BJE?$Q!A%.4
M;&-'*KJ5]J2US,N9)FU*FNO8T\?N@=$/Z)%0>JF,(F^0]A\)N_./.>1RG(N"
MGZS.TGW6$A[*)<GH(_U"Z2+D:%``'49+\BHX_'/QMQ.%8H#+(=OV[6MTN85_
M4R265;$RG$;6#I#=UB23[6Z_LU0[1KWXWL!ZJ8[1!K<LV7#%F"I=RK)OV+AO
M9<F.9>]WI5-1`BCM2.G;8S7BUVYRF(2+D3I"4P%*0?;P7=\#F/F_>/(&\MJV
MO:\;*SDLJLIBQ@F/!<'IJ2%A*K`@F6,,"+DU;O)6Q;IP'XX[#XOX^NG>MZR\
M+;I+R.K"?,:3+R;%?<4DR%:!D(($$I0@@!3-.8,95RI0&H7C?I,0NIC')QYQ
M3)\R1R\9RQL:87+#9!MY7Z\![)6)E,RW!V1!Y()F11]1VY13*4SA,R6+\:WW
M-W++Y)YNW60#?<`1C%2RL@R<W7CPZ1)<.N%"+I&0S65'8D(0V;<LX[M^S8?$
M?CKLL;_Z:W3O?K9`S+*<3;U3*G#&*QC;<,AM,L@*J=<L2@&52EFT1$1-?B8N
M!@8N/A(.$CV41#0T0R;1L5$14:V39QT9&1S--%HPCV#1$B2**1")I)D`I0`H
M`'-$9.3DYN3)F9DCRY<KL[N[%G=V)9F9F)+,Q)+,22222;UTKAX>)MV)%M^W
MQ1P8$$:QQQQJ$CCC0!41$4!41%`554`*````*Y'E"O37%S;YY%PLO)1T,^L<
MA'1;]\QKT8O&-9*>>-&BKAK#1SJ;?Q4,V?2BZ94$5';ILU(H<!5533`QP4JE
MZI8=V$\H->\=^\&4;%N'XO;M@G)ENR#D+1Z)OLLG&Y)8US+;%O!UG-158+&$
MG-0ESK6.$E#HR<&`!!V5XS(W[%C.W$;VJ%@>IN#^VKM>0J-.*4XI3BE:>7E5
M_(`VK8[UAXG_`!'XNIV3MDI1ZWQ99,SR39*_N*CF*;9K/YZ&Q_52JFH,<7!4
M"B9]:;!:S2<+#NFTDC)QC=M"NG#F-OJ?2J;/UTK^*OT.OQ29O8,(ZT;]^57<
MO8B]S4-&C?$(V92/")RX$4DG<)5Y/*3[)"@U*%L:B9HXAXMH0$&_4C5J90I&
MZY^ZHE`1U)O_`+?2K%?'3X,S>.G+]DG:MO?LYG76JSX[NM"D=1\YO0LF+7*]
MN5KI$[2^BX^?C:&^G8V(@U6!E!JY3N&;U5+O33$Q#PO4P4#[?WU1K!94D_QG
M/,2E@:XY#GK]XV/(4SJ5K9SM_FIJ=L&M:2%ROE2KPDG[3:72KJ+P],3R86:0
M.*B\M3WK9V<KF48$0-'U'WU)^`]?P'_<:W7\\YSQ?K/AC)FP&:;4RIF*L14V
M:O5WLCWN4!E"0;0[I1!@S1`[N8G)58"-(V/:D5>23]=%JV347633-"JA-NI]
M*TRO"XXV7\WWE&R1YB]B8XU!UDUM4:XQUYP:E,R%CI*=^95QZI5JS'`]9LF=
MG=8>:6Q6XS$Z[:M%C7.=CG$:W002%M&Q/3I5-;L=1]/I62?E;\]FSS7>N-\2
M/B?HE)O>R-K?,,37/.$VTDKH.-\K6U`5Y1A2*_&$6J[`<&U@32UIL,XG-14,
MHB^2>QJ18=V=9;Z_2HE_=H'K7]3/XGRF='R4SNSY9=X-G)EXP;-+`[>O4F9W
MH-3+/&C-@ME&U9N,QAX^4]%9NV.18B0)"!`(8Q3)+_9Z4T`CW$W_`&]/X6JQ
M3QH^$FS>-/.+N^5#R'[5YJP>M4+=7&NLF5YB3<XZ:3-B>UYU'7CV43<FM/5M
M4"C#N$"N?MTJBB;T_89'H/?"]3!0#<7_`'FJ!:Q=+B;\V5S4C6RRFJH6&W%"
MLFG90:_VD\7DU($+]&%U].[2OR@N`>G\%@[_`.-\>3?RU2N>[;Z?^U;\/):K
M4XI6J_\`E`9:R!?<=Z4^,'7R6G8_8CR`[-5*+CGT%,2L<QK6.:#+1#.2EKR-
M875LC&M*7:YP\B9P9FNR)&UZ5<G$IV)>1'VU(YZ:1ZFJX?`AG#+/C3\PNXGA
M3V*R+9[W5KO:;!)X)LEN?R;]VXO-'J?ZB4FQ-V0S$O$U%#/FL;M&7DD57"YT
M9*%BF"1Q5.?U(GTO4JG2Y0UO?<EJK6FEY`?/-N;G?R#3'B*\.-/I!<P(W9_B
M"Y[/Y!C#R)J??*2N]>9F=T^`L<>[JL'3L/MX)\RF9V8A[`H_.R?EAXU8_P!*
M>.XV^IJF7).E?6NUO/Q/2;!*M[=OSY1=S-C\C3$8Q6MKJ.E8YM$(3I!5>'85
MYUE%3*C@*O"/WBY&"/M&92I#W)HM0-Z)%S4>V".I-_V__BU68^,'PL3/C#SI
M>K[3M]MF\YX0N6.K344-<,R2#F0J4+<9NV8YG8G*R;B+M#2INKK!0-*>PXN2
MUI!TNTF%`(X033.BXA>I@H'H3^^M;OR(ZH/O(7^4-<=,[!G?+F&Z);\(4RQ*
M36-9Q9-]&.J;K7'7!%)C$O7(0X$DWT?V+B*?=T4,8![N3?2I"+R6-[6^E6#?
MX0/$G^\BW5_\56?^\Y"Y^ZIM"?WOX_\`M5W>X>*OW9_"+M1A&OW"R67]`?%?
MG+%T)?IES[>WSPXMU*M-4C;=*NV1R>A8Y,8,CQ91$P=KDXB4?@`\?6AZ*;?9
M59/XB5BL%G\4$I)66=F;#(EVJS"U*_G)-[+/2MDJQC$Z3<'3]=PN""9U3"4G
M=V@)A$`^(\'UJ$?X:VBN0J>G%*<4J@SQZH*L?)SOTT=D%NY6FLQOTFZH@551
MF[SJT>-W)$Q'N,BJU?(G`P?#M5+_``ASK_S(RR^!>(R1G5&(\%21Z!A@."+_
M`&@JPM]Q^RN#/`2/!\G.<PS`I*S[DX4]"5;<XV#`>I!5U(/I9@?J*^WSD5[W
M+/5*V220FJ<+<,A5ZPKB5<4T_N=*@22"1S-OY<!6C:B^$`)\X@F/;\0Y+\4,
ML)+R#`B/_P"PDQ\:2,=.O;.0I/7IT:6/UZ=>M3?-_`>2#B^Y3*3M<63F12MU
MZ&88CJ.G7W)!*>G7V]*G3S7UR5F]/H63CFYEV=/S72['.JE*<09Q3JMWBHHN
M#B4I@*4TY:6:/4P@'54`Z]1`!Q'XN9F/B^2)H)F`DR=JFCC']IQ+!*0/_'$[
M?NK._F?@9>9XD@R,="T.)O6/+*?[,9ARH`Q_\LT:_3JW[JG#?1)B>;T7<2!2
MC'I[V833(?N.!0DUHNXJ010!$04$3R3=,0^'I]0^?Y1'KB_B%I!B\L2+_&/$
MLX_](:(/Z]/PD_?]G6LR\\I$V;P>24?D#G.VB_7\9$QC].O5E'W=/=TKN$O"
MOD/(O1;$^:E)#2FFF28:`>K*MQ(XL,#FC&CZ>:LD15%P1VSAK(T.H;L*!TE^
M@"8"G`MMQ\J)_"65@PL3E1\GQWD4`](Y,+(6,L;6TL\3@=>C+U`N+W?*P9X_
MD7A;E.@&%+PW*CA8D=9HMQQ6E51>^I8YD)-NJOT)LULVN:JK=M.*5#;S7_$<
MAGZ!VB=U,5<Z5G$UCP;!WCZ_9TP98MMMLKUXL%8&L)31*<Z%_:*JP=>^6CU)
M%'T/22<$1453.J%A>_UJ9.*C3BE.*4XI7P(]`$?X`$?\@<4KSJ/P^JDOL1Y#
MMZ-S\LRQ+?EN#QLN^7D9F(8OW;V^[-9/D+1>LC-)5QW.86R"G1'S`3MB@=PR
ML#Q(QRIF,128_95&+J2WUKT6.2U6IQ2J+OR`/%0S\I&DLQ"4B)07VEP`6?R=
MK3(`I%M',]-J1S8+GAIU)2QF[1G#9@B8=LV3,H[8MT+`PB';IP5HU734B#:I
M774+?6M-V-VNW_\`+CIYJ'X#:Y1\F16S&&,[S](VWLEBCY:%85O7#7MY5:GC
M>=V`["PJL/%X;LEG=,+'%235V_>3E)@%TUG4_)HLQCZ=?I5*Y=0GUKT7M0]5
M\3Z/ZRX@U:PG&KL,<X7IK2LQ*[[V8S=CD>]>3M%ULRT>U8,'-LO5H?/)B550
M0;H*2#U44DDD^Q,L/4U6`"BP]*T-?Q"H!?93R5[R;GY<E8VSY=88TG;&NM(L
MV2C]UD'9?*ZEDO>1(<%4E'$;(()59_'*JH')T:V%5$W4JO3D3]E4HNI+?6O1
M?Y+5:G%*\_BK?\\*Z_UCN/\`PL)SDW\M4?\`O?[?97H#\EJM7P(@4!$1```!
M$1$>@``?$1$1^```<4K1L\>N893RX?D^9NWAH`O[-JWHKA^T8RP_=UV`C`-X
M)Y`6;#=-1B9./;->XV9[/><A7:$3E`]U]&%RF<"*-2)IQ^E4U]SDGT'^W_K7
MQ^4QKI9M:MQ_'OYD<6UU^=IBK)F+JAG67BH>.<Q$'8</Y'CLG83M-D8QR+2:
MF7-UC5YNOOGCY<6@-H2'C@.D=PB14/2WUHXLP?Z7ZUNXTVXU3(=0JM_HEBAK
M?1[S6X.XTVVUV0;2U?M%4LT8UFJ]8H*59**LY.&FXAZBY:N$CF2605*<HB40
M'D*J5HD_AW52LY%VO\L&R$_%G<Y0B7>+*M"SSE\Y=NH^MYTR/G.]9#C5%5#$
M(^5FI_$%?5.X4)ZO<Q^`E!0X#$]`!5).KL?K>M]KD*JTXI7GT;V[-9%U#_*\
MM&<<6:OY:W"N%>P54XMI@O",=.2V1;"TL>KC.%?2L1'UVI7:47:UMN[%Z[[6
M!RD;)',8Y`#KR;Z52)M)?UZ5;I_B&=Z/_P"=;R@?T=Y@_LU<A:HZS]AJY7R>
M2*\QXGO(7+.HUU#N93QX[9R+B(?%.1]%+O=;;^Y6C7A%$D5".F*BHI*`8A!`
MY1ZE`?AR`]:G;\)_95-7X>W]TG+?UL<R_P"RV+N1/K4D?X*VH^0JI3BE.*50
M7@63:8S\UNPU3ENAGN3JK9XR%%L!?2*[G:]CS-2?K]0`>H5^N.`/T^/K?]?.
MON6X[[[\7=GW''/Y6!/$[W]2$ER,$@?^25;?W17"?#,^+CWS0W[:\E?SMSQ)
M(H]/H&?'Q-PNW[8H&O\`WR*R]\NF,%\CZ6W"28MWKR2Q79ZMDYHT8HG746;Q
MZ[JJSZZY2#U*QB:M;GS]8X]2D3:"8?@'4-;_`!RWU-E\GX\$I58=PQY<4LQL
M`6`FC`_O/+"D:CZE["MK?+/C4G(?#>5E0!VGVO*@S`J@DE5+02DV]%2'(DE8
M^@$9)Z"I!ND2;>#QW+HM19R=CR_@>!LK%K#/TF[`,K0T=&6IC!"\4%1-LVCL
MG0!&+LIQZIE24(80$!$+1M>0OBKS2&D#1X.W;O)$3(I+?I)&:(R6'4EL63N(
M1ZDJ1>KYO.*WFSX\%8RLNY[ML44RB)@J_KX52<1!CT"KFP]J0&U@&4D=:BR"
M5G-P?&CCVQT1\Z<YDJU)IUJIDL[;1CV?3SUKY*M#`J@1XY19,9"X66G.&J2Z
MYB`5E+@J<O882CD.6,7QMYUS</=T5>,Y.5-%.@++&<#<5/0V!9DACF5F50;O
M#I!N+UBF"<WR[\:=OW#8)';F&'@X\V-(1&\PW/:G'N74P19,F2!T1G(`CR`[
M+I)4SQ*WC'N7\7Z_[EU]X5G%8^<(Y%4D3"B\-"T.X0CVAYHKEH<1ZZA46M%C
MY->3E")&4*C*U5(3`8$1`<1Q]JWKC6_[SXOS%+3YH_3!>J]S(A=<C!DB##J9
MV58HKVO%EMU!:L^GWOC7,>,\?\T8CB/$VZ^9W.CF+&GA?&W&&9D)`7&#-+/I
MU6FPEZ'369R:A%2$52.11-0A5$U$S`<BA#@!B'(<HB4Q#%'J`A\!#FKF4J2K
M`A@;$'Z5N965U#H05(N".H(/U%?WR%1IQ2G%*<4IQ2G%*<4KS%=.[RG^-CY^
M,JXKV#AK+!:L9);6O%#*].V,W,=FLV5;G$W#!&>8LPA!M;@G2Y>H1\7;73%*
M2-'>VLS-DB\DF96QYO450'L>WTKTUX2;AK+#1%CKDO&6"O6",83<#/0C]K*P
MTW#2K5)_%R\1*,%5V,E&23%<BS=PB<Z2R1RG(82B`\EJO7)\4IQ2M(KPP`'^
M)^\U(]`ZA7M@P`>GQ`!V;PX(@`_P#T#_`"<B?0537\9K=UY"JE>9)J5;2?C<
M_D$9,Q9G.)FJ_JIE@MFQ?$W-V,K)-6NL.8[Q%6O!>;&[M^G7VEG)CJ<J+")M
MSULD[&/%A96S(CMXW*BM-ZBJ(]DEOH:]-9!=%RBBY;+).&[A)-=!=!0BJ*Z*
MI`426153$Q%$E"&`Q3%$0$!ZAR6JU?;Q2O/XJW_/"NO]8[C_`,+"<Y-_+5'_
M`+W^WV5Z`_):K513^1QNXXT?\5.>)ZM2ZT/E+8'VFKF*'C9*4]RSG,M1LT6[
M3362AGC!_7)6MX;@[-(14D"I2M9QLQ`>XRA2&B!<U*YTK>M6WQ0^'?\`(3QE
MJS3,V:+[BZPZM8TVVJE)SA]GVRPRSR]3$#-00N\>3=I]'5[+,6Q&3J$HD_:-
M&LPJ#=O(`"Z:+H5T23&WUJDHD`]MK&LE]T_$[^3OFK5C-E%V=\B6JV:\%DIK
MB\7_`!;&S%G++W%EBIXSRC%QD&$1IE57ZTZ6?IS15DD619IKNDTTU5`2.?K#
MVCK4Q65O:;5:A^)UO$&TGC18X(M,^,IE72:T?I%)(/7[N0FG&'+,$A:,&3KL
M5FR35C$L8U.7J,8V244%)G3BF,!>\O6!]:C&;K;ZBM>3QD;2.?`OYR]P]5-N
MUUJ#@'8&^RM'F[Q*'CXZMPS=2YRUVU<V#DUVIIENG0IBFW-VU?$]VB6#1LRJ
M\@=-2)<M@C]*E!TR$'H":](V*E8N=BXV<@Y)A,PLRP9RL1+Q3QO(Q<K%R+=-
MW'R4;(-%%FCY@^:+$5162.9-5,P&*(@(#R6JU?OXI6E7_P#M*_\`3A_\/>1^
ME4_^Y^ZMU3D*J5@-Y6?[KKR2_P!0;<3_`-O&1>1'K4K?A/[*I5_#V_NDY;^M
MCF7_`&6Q=P?6I8_P5M1\A52G%*<4JAWRQUB5PAFS5_>2GL5CN*?;X6H79)E(
MEA_JRE>D'%OJ\8Y.R(5^LE;*\2?BI%<XJ)^R2;MS@)#%(;KGX\9^/RKBV_>*
MMS<"/(QGFA)77H$JB&5@&]H[,AQY8U%CW&=QU!(X4^5NVY?"N:<9\U[.A,N+
MEQP3@.(A(T+G(@1BOYA&1$,J&9O<.TB1D6(4W;QDC4<G4>/EF7TRV4/(=4:2
M+3W30CR'LM1MD0FY0]RQ?(BFZC)F&D`[T5D^ATE!*<OQ$.<KY$&Y;!NSXTNO
M'W?"R"ITM9XIH7(-F4]&1UZ,IZ$7!KM;%R=IY/L<>7!V\K8MPQ%==2WCF@GC
M##4CCJDD;]59>H-F'J*KP\>]9E]>K5L?IQ8Y5XZ:XQO:&2L-C,R#AP\F,*9,
M24&+=0@.V\8D]9P4U$*)31X]H1BVL3YT3O,90HFW1YFSL?F6W;)Y,P8T5\_$
M.-F:%`5,W&/N62Q8JSH]X.XYD?&CC-@%KGKX^[;D>/\`<^1>'MQFD<[9G_K,
M#NL29-NRU';>+4$#+'(A&5V8EACS)95U,SU(;"%KVK.U\C(!)C`8FW,>-D&\
M6L<K6K5G9^`2`4V[!$A6T9%/<Z5==PMWB!W4C-PPIG4.99HD2S396;Y!\>)"
M8^]R/C"$EP+RR[7(>I8]6<8$H46Z+'!-J`&F5FR'&P-N\6>4YLKN=CB?,I45
M4+*L$&\Q@V54LJJVYQ%FU@EY,F`HY/<@5.YW2JN-=+W8M@*8X?)8DM)BO]C<
M9,VTC)1L<Z*8$U=A*%!,$7AXVS1"!P-<6;-$A)Z(2/("1649$(_MFU;@G-]I
M@X;N@0\DQ_;MN4Q568?3;LB1BH:)STPW=B<>8B&ZX\I,5WWO:Y/'6^Y/D'9G
MD'$<D:]WPE#NB$>NZXL2AM$T8ZY\42C]7`&GTOEQ*)N]1E,6:)-LA:WW:MGJ
MMCCFDHCC]R\+-X0MC3V9#LY2B2==.Z<8ND)HJ")#R,*22@CE5</%X)_(+"ZY
M:9MTCD+;)SG$G&X0.5_4JO;SX3?JF0DEAEHER1%.8L@62),R&%>W5\CV?*4C
MDWCC<,=MNR8U?]([]W;<@!?:^-)$6;!DDTJIFQQ-BD-)-)@9&0_=KMR>1[GZ
MLJ@O@3*B8Q@G*V=(S6$G#"PF34:)B>"..7T9`B"P.3G3&2;1J@D0/WD(<4R*
M6T[%M6F-DWG;B']08\\-'T)_,_HBMQ8`]II1=A8D7(NPY+O8:5)./[M>/T*R
M[85E(*C\H_Y@&L;E@9DA.E3<*VE3Q"LWG*Z(I-Z]3(K#<>Z(H1[/Y)DX:Y7B
M+.BY3*=.*Q]CZ9F*2\^HLO4%M(.;<(,5O3.M&.R`=`?4N)Q':F[F;E2;I.I!
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ML5]L=(M3=Y\?'QAME@>@9LJA"N`B36F,40M-36=JLU7C^A7Z$<1-\Q[*/?8)
M)KNX22CW*Z!114.9(QR&5`BXL?2M9*T?B3?9<PW6TS\KVX6L=;CG2#N%K\LQ
M=7YQ`G3?O9,Y(B7QQD[7DK4B3Y5!5L;VIE45$CG.=514#)QN/LJ72P%E8@59
M+XM?!:R\<N9938NY;R;-[7YBEL;36+'9L@OF\)C(:W8I*H3<LN%+EY7(MJ^K
MIS%*9G:*?<OHMT0%,Z2Q@*J6'[*F`/JQ)/WU?AQ4:I#TO\-Y]0_*!NMY(!V+
M+D$NX$?D%B7#88C&J&QY]]Y-IV1O5'(0Y-L@6SZ5]I^S[?H<;Z_N/5ZI]GI'
MC?I4H6S$_;5WG(5-6)NX.C6J>^>+Y#$NU6%Z9E>MKLI!M!2LS$M27>@O9(&W
MKSV-;TW23M-!L`G9H][F,=-S.$T_1<`LW.HB=0@$6/I6LM8_Q'RT:08AIKY8
M]R=;JY%BP4C8BQL0R!(1SENX<OG:[&5Q7D/6MBT%62,BNAZ<>4S=1,YA,J90
MIDXW'V5)I8"RL0*LB\7O@=KWCHS?);(VO=79;:K+CVD63'[<N1GC&*QVT@[8
M\K<C,R`U22?7NS+6;WU81]!V6P)HD04.0Z"INU0(=*F`-[DD_MK!O?\`_%]N
M>Y^_V9M]:%Y&I_6RTY4DJO(1,!4]?96:L5(^@8IJV*WR+#(\-L=C^1>?7(ZO
M+'5,FP9]$'IVY@4*!CJ37%K&I"C:M2FQJ`/\)]M__OW]B/Z(,G_VT^/;]E1_
M-_MG^)JT+=?P-K[U8I\6F$,Q;:R<CC7Q^5ZE0.8X]_B>0F;#M\:!KV'ZI:9:
M4M;C,;:5Q7*VVOXXE$RN/])5VBUC6644=G;D]2%Q0J2`"?V_?6PDS9M(]HU8
M,&K=BQ8MT&;)DS03;-&C1LF5%LU:MD2D1;MVZ)`(0A``I"@````'(5/7WB`&
M`0$`$!`0$!#J`@/P$!`?@("'%*UP/'E^/\^\;OD8S%N=@W;.,;8,S*YS!$3&
MH;;7M>&AX'&M_LJ]TH-%KV1R9QD6K5QB*R,8DC&34K*BKF*:.68)-O?*+)1O
MT^^I`I#$@]#5N>Y'CUTTW^H[FA[98"HV5V1FC5I$VAZR5@\DU(K&0&59FI63
MZVO$7ZI$3D#&.JBQD$6KQ-55!TDNW7714A4Q`(L?2M;&=_$MG:/+KAI_Y==P
M-;J:BY2^@5>2B).ZO(.+]JZ(O&DFL<9@P"S<"+Q\L9%0D<@";=4Z1R*G,988
MW'U`J72P%E8@59WXJ_!W'^-C,5UV%MFZVQ^VN6[CC*6Q$93)KI"+Q_%U"<L&
M.[6_?-ZK)2]]LRMP2FL<-DVS[[@(U1C7"K<S113M<%A4P!O<DG]M8>^2S\;2
M];Z[XW;>C'GD/LNK%EMM6H]7:0%/P9,6&?@4*C2(RE/%6^0X/8?&L@LC/MX\
MRBB)6*`$(J*1C*@'<:((M8U*5;5J4V-8B_X3[;__`'[^Q']$&3_[:?(^W[*?
MF_VS_$ULLH:0S[CQ@SGCMM&<Y6X62QZ8W/4R9V*GJN]D)B4DKCB2:Q>YRG)T
MR0N[]_(NT59@9`\<K83*+B3T1?%$WK!#ZU,02+'UM6KO2/P_-@<9PHUO&_FG
MRQCZNF>+R)H&D:]W6J0HR#HB2;E\,7`[C,&(O'!&Z95%?3[S@0H"(]`Z1)4^
MM2!9%%E8@?OJP;QV?CW;'Z.[CX>VCOOEGS-LS4\8?J#]6PA;,<7N!@+M]ZXM
MN^/&/OY:9V?R)&M/MN2MJ,NEZD.\]19@0A?2.8JZ</;]!UJ8=R_N8D?M-;0O
M(5-3BE13G##5+V"Q7<<09!;NUZM<XY-F\4CG(LY..>,GC:5AIF+<]JB:<C"S
M+%!TB"I%6ZAT0(LFJB8Z9LAXIR?=.&\@QN2;.5&?BN2`PU(RLI1T<?V71F0V
M(8`ZD96`88ISCANS>0.*YG$=_#G;,R,*Q1M+HRLLD<B-U&N.15<!@R,5TR*Z
M%E."/C6NT_2(;(^DV5Y4I\OZQ660912*[GU!LV'YM=M*5*SP)G3@TD\AFJDP
M4A"&2*$=&O8M$_890$4]N><MJQ-UR<'RGQZ/_P#F]]@4L0+=K,0%)8I+#0KD
M(;V8]R6/(87"ZFT9\;]\S=EP]Q\*\ID'^K^,Y#JH+7[V#*PDAFBU'N-&IE``
M*@10RXJ]"P19CVXP-DFQR%9V,UNER0NS&'HB28UR+DU4SU/*M'D%3.K!BVUL
MW2J#02R(F.M&+G50(C(=O<JW,*3YEC/CCEVQX,.1PKF\1EX-N<BM(ZW[N).H
MM'E1$`GVV"RJ`28[V5P&AES'RWP;DNY2XOD'QS,(?)&S(XA1[=G-QGZS84X)
M`.OJT)8@++;W1,RY$/SB[)>"O(?@NR56YU'M?L%TZOFG#%L*YC[GBV^,E'"9
MVZX"6/F8\R,DP<'B)=$K913T%"&*W>-WK-O#?]CY;X7Y;!N.UY/Y+@RX6;%9
MH<K':QO_`#(UU91-"2P&I6!>-XI7EXQR3@WR&X-D[3O>';)C80[CMT]UR,+*
M6XM_)(HUJYQ\A0A8*Z,(YHYX8_Q25QS7J:]35R(\D<WZK1L:V!]EMR51[G#"
M<='H&:+/<G1<2Q,IF&FMP!L=6>8-DYQFV!VZE$W7HBZ7K0;9Q7R+$5V54VKR
M#)(=.&++@YS,;VQ7=@,.8^X""1S`[=N.`IJT)2RMYYIXHG5N0L^]>*HH??GG
M4^Y[<B`B^;'&K-N$`_+!R8D&2B"67+$A0RRRQ0\88;F#O\K:_7-:LQV0'KV7
MEIG#-NBI7'%NE5%DFDO-FICU&V8J^YW3N-`C^59Q:$NNLF<KAR8W>`X]O&_\
MHQE3CO,\43S8:*B)FPNF3"EBR)WU,.7V@'O'$\K0A2"B`6K*^.\9X3E/+RSQ
M_E]C'W!V>23;\A7PYY+JDDOZ8][![Y,6B69(5G+!A(Y:]=FE*ML"B95*J9DQ
MT1H"B?ME<@8/E;9+@@4I_4*[>4O,F*HIPY44,`@HFP;D*4O3TQ$1-SP0;APQ
ME!W#:\[O6Z_I\](DO]RS864X%OH9&-S>]NE7++VOR")F_P`JWC;%QBWM&3MD
MD\@7KT+P;EAHQO;J(E%A;3?W5RC"D9)7:D-9LU3?U/K_`"XT2E46L01B@=3M
M!",MT1DN:0,9(2@<1E%.IRB8O8`@4OGGW;8ED/\`E^U1#'MT_43SRR7^TM"^
M*AZWM^4!;H;^I]V'L_(SCJ-VW=VRPUR<;&@@C(Z^W1.,QP"+7/>U7N05!L(6
MLN2M<]0@<P[J5GK+E>_JMY!*FQ3NPYAV,R[*MX^2)"II1B[R8MTBR!&+<-(X
M[I1E7XSH+=([1+H0,IP=BYOY*TY*1PP<=PP5[SB/"VW#0LO<.H*D*M=U>4('
MR)![V$A%ZP;=.3^./$.K#EEGRN69VEAC1F;<-XSW"R=H:2TF0Z^R2.`RM'BQ
M'\I&B!TU+>%IW-EJC+!9LR4RN8S+*S!?L7'49+!9K17*NU:IH"YR':&3E2MO
M[3.R0*N0:11!:1S(4$3+N''K&+C?*<3BNWSPX'&,J?/,<7Y^2R=J*64DFV/$
MP[BQ1K9=<IUR/K8*B:`<NX5G\UW7$R-RYEA8^V&6?^FQ$D[TT,"J!?+F4]II
MY9-;Z(?RXHC&A9I1(:FGF+5FE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*56!N=JCE9_E:G[H:LS#1I
MGO%D+[*7H,JU]6$RU6H\SDWT05473%1.4=P[YY'KH*'+[]LH@5!PQ<-4U5=]
M>,/(7'X>/Y/C#GT3-Q'<);ID(;/B2-;WV(8:0ZI(K`?EN'+I*CE5YE\S>+.5
M9/*,3S)XRG"\ZVG'TMB.NJ/-B0L>V"'0JS1R2QNE_P`Y601O!(@=\E=2=L*?
MMG09.T0D)*4NV5*;6J^1,=SYQ4FZ98D>\P-5UC-6!WC%V1,_HKF;H&$Z2J1T
MTU4E"%P?R-X\W+QWO$>!E2QY6W9,0EQ\B/HDT?V@7;2PN-2ZF%BK!BK`ULCQ
M/Y4VGRML$FZ84$N'NF+,8<O%EZR03`7TWLNI#UTL50DJRLBLI`ZYEW7"ZI98
M8;&ZS3U+H&95XI2M9*B;C%R;C'V;ZJF5H>'CKP,&*DE#6&N.6*?L9UBW4D2-
MQ]NJ*S8A$`]O&^;[4W'GX5SN'*S.,B02XSPNHR,&7KK:#N>UXY`QUP.PC+>]
M=+DM5OY9X[WE>4+Y!\:Y.)M_,&B,67'.CMA[E$`.TN4(SK26)E`CRHE,RQDH
MVM`J5Q%6WDJD?D&.P]L90;7K%E":42;UI*^+L9G%]Z=&;@X61H.7H4"UF9]J
M"B29_>IQAO<N46H%%X<S<GIW#Q-N,VS/R7A.9C[]L,0)D..&3*@%[`SX;_FI
M>Q("&3VJTG^$`Y\&V><MGQ^01\0\AX&7QGD\UA$,O2^'DL5#,,7/C_(D"DA2
MSB$%V2+_`!V,2][M.G&%Y>>D[G26UIP5D&8%`\G>\!VF1Q?*RRR$HK,F<62`
MAA/0;JN[?KJ&<'G(>2,N4XE.(E^'+3M_D[E.-B1[9NK8^[[-'?3C[A$N4B70
M):.1_P"HA"J`%$$T86UQ:KYNGAKA67G2[SL:96P\@FTZ\K:IWPI)-,AE_-BC
M_I<@LY)<Y&/*7N0Q(KC%L-[6Q[QT>N[E^_CU!4(S:Y)UWQQ9GC5!5L5,3+/\
M?RN(DG;UNZ#U$5/;II`0>Q5)4?GYZ%Y/X[FA5<SB^B<?B;&W+)B#$&_1<A<O
M2I'0C43]59?2O*W#/*\&2[X'-#)B&^E,O:,.9E!4#J^*^#J8-[E.D#K9E;UK
MC3ZSYMM46ZBLH;LYOD6SIP@L*6(JOBC!YB)($:?S9.<A:=8KRV37725,H*$R
MB<Q%0*`E[.XU?_7?%-OR%R>/\5VJ-U4C^LER\\7-^O;DFC@)`(MJA-B">M[#
MS?\`UGSC=,1L/E/-M[EC9@?Z"#!VP@#3T[L4$V0`2&OIG6X('TN9.IV)]?M8
MX6T7&.8UJB)OA-(7[*M]LJS^RS/K.$S"ZN^5+]+/[!(-?>'`4TWL@+9%0_1(
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MC=6.3F&:CD2D8_BH'*V4G68KV1Q)/9V\.*S`T]N[5D'Z[M&.BZ]7FZ+1A%Q3
M=4J"7>=94_:)NI""1!+`^4;ELF[;S)E\>V]=LVC2JQP"628@*H!9Y)"2SN06
M-@`+@>Y@SMLOA>S\BV/C\6!RO=7WG?0[M)DF&+'#:W+!$BB`54C!"BY8D@D:
M%*QI*?,>K*J<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4JK_`&NU=S36\IQFWNDSF(B<T,4$X[*>,'OM
MX^LYSKI5DS@,H15[&13N=;IE])R1RLU5=-P3<-7K5^S1]UOOQYS[B^=L$GC?
MRFLDG%W.K%RA=I<&2Q_"0K.J'U0JKA&NDD4D$K]OF'RMXOYEMW)XO+?A5H8>
M9Q^W-PVLL6Y0W%]8+)&[BUI%9HVD2TL4T63#'W)JP;N]CS)<LUQME"(E]=-@
M"BU0>X9RR4]>E)9=V<C=F]Q[-R;>-C;Y#RSSU4V0M>Q\OZ"A_:@EV*J8ORSQ
M3O6QXYWS8)(][X>02N;B?F*@%RRY"*6:!T6Q?5>-=0'<U:E7-N$^:]@Y%E_Z
M;Y3%)QWGJ.J/M^<1$TC,0%;$E;2F5%(UUC*6D?26$?;*.^4E_P`>TC*=3EZ+
MD6K0UQJ,ZA[>4@IUFF]9+@4>]%=,#@"K1\T5`%&[E$R;ANL4JB1R'*4P8!LV
M];MQ[<8]VV3(EQMQB-UDC-B/M!^C*PZ,K`JPNK`@D5L_D''=CY5M,VQ<CQ8<
MS:9UL\4BZE/V,/JKJ>J.I5T8!D8,`:PO:Z)R&,@7-JULSG#`3,J0-HBA24DP
MS5AR!;G,"KHL5CW):;]VV<O7'511<LL"P"8P%,4!Z!M"3RW#OUAS_8MJWB3U
M?(56PLV0CH->1C6!"CH%[6GH+@UIB/P7D<9U-XNY+O>P1>B8KNNX[?$#U;MX
MF7<AF;W%S,6!)L0#:N:5KWD?AC%80^3-0;HR222`L_<L9Y7K,Z[4*D5)0SF)
MJ=[>0J/>9/U1%(X!ZBA@`I2`4H>89O@_*'>R<'DF)*2?RX,G$EC'6_1YH1(;
M7MU'H!<DW->MMO\`D?A']/A[EQ'.@`'YN3B9T$K&UCJCQYVB%[:O:?4D`!0!
M7&/<9^12Z("28V@P3AA4BQP(?$>!WU\%PAZ;3TS+GRQ:UBHJ&4(J`E33'M`W
M4#B(E*E6CWWPIM9_I=AW;=`0/_F9XQ[&YO;])'U%K=3ZVM86);SR<:^1.]#^
MNY/L>S$$_P#P-M;*U"RVN<Z7H;ANB^E[W-P%^F$\=N)YNPL;WL;;LB;67YB=
M!PS?Y>GUC4J#<E-ZKQO5L9P`QM5C("17`#JQKLLBT$2A\O7J(SY?FKD6-A/M
M/"<;"X]L[W!7#C'><6L#+DR!I&D4=!*G;?[ZDP/COQ3,W!-]\BYFX\JW]+%7
MSY3^GB-]3"#$C*Q)$YL6@D,T?0>WUOG3%Q4!4X-I$0L;#UFMP+`K9A&1;-E#
M0<-%LDOD0:,FB;9A',&B)/@4A2)IE#]@`'-2Y&1F[EEMDY4DN1GS/=G=F>1W
M8^I8DLS$_4DDFMYXF)MVSX"8>#%#B[7CQZ42-5BBBC4>BJH5$11]```*P)RY
MO2UE2O,?Z4P$=M5FU0!35:5.0]UC:@LG)5FK.TW2])*-*FZ9#*BFFFR2EFQG
M!04,=RW*0#'V[QSQ-)CE=X\I3/Q_BP]#,MLG(86)BA@-Y@VBY+F)M)T@1N20
M-&\L\V)F1ML?A>"'E/,F'40/JQ,5&U*L^1D@KCL.X`%A$\;.+N710"V66"(;
M+]?Q-3HK/5PA[YEQ!I(+7.SU^+90\,[>OIF1?L6,>RCXN%:"W@HARW8`N5HW
M,Z]MZQR`=0W-><NRN-YG(\G(XAC28?'"RB"*1F=U54569F9Y&O(X:327;3JT
M@V`K:/`\+E^W\3P\3GF9%G\M5'.1/$B1HS-([*JJD<2VCC9(M0C37HUD78DR
MYS&ZRZG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*Q[V+U<PQM/46]1S#5QF$HL[]S6I^->N(BT5.2D&
M1V2TC`R[4?E$2BFH=HZ3=1SE5!$SALMZ28%S/A7/^3^/]Q;<>-SB,R!1+&ZA
MXIE5M061#^\!T*2JK,$==37U]Y%\7\-\I;2NT\NQC((B[0S1L8YX'="A>)QT
M/T8QR+)"[(C21/H6V#L7@S?_`%)4;#@G*\9MIAR+64*EA7,KEO7,CQD(9\P;
M,8BH9&>*KM%W$1`-O3(HY?,(M#H84(=0QBIAM?(Y;X>\C!O]6[=)QWDT@%\[
M#!DQVDTL6>;'4`V>0W($<DI%@^4`"U:0Q.#>>_$K*>#;K'ROAT1-MMSR(<I(
MBR*D<&4Y87BA4*"9HH`=13"8D*.=C_*13ZC],9;-:\;$ZU2;Q1XDZE;50I*>
MQ^@=HX!N`QMI;-8F?GTECG*`*-H,R7<8.AA`2F'R3>`=SW'N3<%WK9=\QT"V
M6*=4G-Q>S17DCC(Z]&G!L#T!Z5[L?Y1;/M79@\E<>Y!QO+D+`M/C/)C#2;76
M73%-*#TZIC$7(L2""9/C_*'HA)D4.VV`BDP2,4I@D*5DV(.(F`1`4TY6E,CK
M%Z!\1(!@`?VCRP2^`_+<-@^SN;_V9\5OXZ9S;]]9/#\GO!<]]&_(+?VL7.3U
M^S7C+?\`=>WU]17X)7RI:'11EDSYU1?+I)>J5&*Q_E*1*L(D$Y$D7C>DFCA5
M/TZ=#+%`HC\PEY5@^/WEN>Q_RG0A/JV3B+;[R._JM_TG[KU1R/E)X+Q]0_SO
M6ZCT3$SC?I>P;],$N?3\0`/J1UM#7_V4Y-S&1NWT[TTS'E=M*IR+!AD2_((4
M+'+&;:?(7U9=`TM7I)FW.(>LDYG(5?K\@"4?FYE'_P!&[#QDE_)?)]MV]XRK
M-C8Y,^0T9^Q6T2*Q^A7'G7Z]?2L,'R2Y/S%5C\0<.W?=(I@Z+EY0&/BI,IM[
MG3N0N@]6#Y>,P/MZ$W''H::[7;=.&<[OAF`*70.K5XVUDP0\&+KXJIG8N@1N
ML^+F89R"K9_'`?M%>P+$!8XLY%D/R\K/Y-\>^.$;$\2;;^JWBQ4[GG#5)8W%
MX8[(R@JQ'1<93I'<AE]:HQ^'/*?EMTS_`#INYP]B)5UV;;2$B!&D@3R@R(Q5
MTU=6RV&INSD0^@LOQ+A;%6":HA2<14:!HE;1.595G#-C^ZDG94B(!(SLN[4=
M3-AE1;I$3,[?N'+DR9"E%02E``T7R/E/(>6[@=TY'ES9>:18%ST47OIC10$C
M2]SHC55N2;7)KI/B?"^*\%VL;-Q+!@P=O!N5C'N=K6URR,6DF>P`URN[Z0!J
ML`!)_+!63TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
13BE.*4XI3BE.*4XI3BE?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
